Skip to main content
. 2009 Nov 10;101(11):1846–1852. doi: 10.1038/sj.bjc.6605377

Table 3. Most frequent grade III/IV adverse effects (NCI-CTC) observed in BDC and GBC trials.

  BDC
GBC
  Grade I Grade II Grade III Grade IV Grade I Grade II Grade III Grade IV
Haemoglobin 18 (47.4) 14 (36.8) 4 (10.5) 2 (5.3) 21 (58.3) 18 (50.0) 2 (5.6) 0 (0)
Leukocytes 21 (55.3) 17 (44.7) 15 (13.2) 0 (0) 26 (72.2) 15 (41.7) 2 (5.6) 1 (2.8)
Neutrophils/granulocytes 15 (39.5) 12 (31.6) 9 (23.7) 5 (13.2) 18 (50.0) 13 (36.1) 10 (27.8) 2 (5.6)
Platelets 21 (55.3) 11 (28.9) 3 (7.9) 4 (10.5) 16 (44.4) 15 (41.7) 10 (27.8) 3 (8.3)
Bilirubin 1 (2.6) 10 (26.3) 7 (18.4) 8 (21.1) 2 (5.6) 10 (27.8) 5 (13.9) 1 (2.8)
AST/ALT 29 (76.3) 16 (42.1) 9 (23.7) 0 (0) 27 (75.0) 10 (27.8) 2 (5.6) 0 (0)
Alkaline phosphatase 26 (68.4) 15 (39.5) 7 (18.4) 0 (0) 24 (66.7) 9 (25.0) 4 (11.1) 0 (0)
Nausea 27 (71.1) 12 (31.6) 1 (2.6) 0 (0) 28 (77.8) 16 (44.4) 3 (8.3) 0 (0)
Diarrhoea 15 (39.5) 2 (5.3) 2 (5.3) 0 (0) 13 (36.1) 6 (16.7) 0 (0) 0 (0)
Anorexia 23 (60.5) 7 (18.4) 6 (15.8) 2 (5.3) 29 (80.6) 16 (44.4) 8 (22.2) 1 (2.8)
Oedema 5 (13.2) 8 (21.1) 6 (15.8) 0 (0) 6 (16.7) 7 (19.4) 3 (8.3) 0 (0)
Dyspnea 3 (7.9) 3 (7.9) 3 (7.9) 1 (2.6) 3 (8.3) 5 (13.9) 3 (8.3) 2 (5.6)
Sensory neuropathy 24 (63.2) 10 (26.3) 3 (7.9) 0 (0) 26 (72.2) 19 (52.8) 7 (19.4) 0 (0)
Fatigue 18 (47.4) 27 (71.1) 3 (7.9) 1 (2.6) 21 (58.3) 24 (66.7) 5 (13.9) 1 (2.8)
Fever 11 (28.9) 12 (31.6) 2 (5.3) 0 (0) 9 (25.0) 10 (27.8) 3 (8.3) 0 (0)
Infection 6 (15.8) 11 (28.9) 3 (7.9) 0 (0) 5 (13.9) 13 (36.1) 3 (8.3) 0 (0)
Febrile neutropenia 0 (0) 0 (0) 1 (2.6) 0 (0) 0 (0) 0 (0) 2 (5.6) (0)

Abbreviations: ALT=alanine amino transaminase; AST=aspartate amino transaminase; BDC=bile duct cancer; GBC=gallbladder cancer.

Absolute (and relative, in %) number of patients.